Project Grant R21AI194027
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $149K
Funding Federal Agency
Awarding Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This $167,500 Project Grant awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel and effective medical countermeasure to treat the gastrointestinal acute radiation syndrome (GI-ARS). The grant recipient, The Feinstein Institutes For Medical Research, will conduct research to demonstrate that MSP68 can mitigate GI-ARS by promoting the recovery of gut stem cells and reducing intestinal damage...
- This Project Grant award of $153,000.00, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), focuses on investigating potential radiomitigating strategies for gastrointestinal acute radiation syndrome (GI-ARS). The research project has two novel approaches: 1) Evaluating the mitigating effects of dietary methionine restriction on GI-ARS following radiation exposure, and 2) Exploring a second approach outlined in Aim 2 (details not...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $155,000 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the mitochondrial serine/threonine phosphatase PGAM5 as a potential target for mitigating gastrointestinal acute radiation syndrome (GI-ARS). The research aims to examine the role of PGAM5 in radiation-induced oxidative stress and modulation of Wnt/β-catenin...
- This Project Grant award, totaling $156,000.00, was provided by the Office of the Director of the U.S. Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The project aims to develop a novel, dual-specimen biomarker strategy to improve early detection of gastrointestinal acute radiation syndrome (GI-ARS) using angiotensin-converting enzyme 2 (ACE2) as an early tissue-specific biomarker. The study, conducted by...
- The Project Grant titled "Engineered Microbes to Mitigate Intestinal Radiation Damage" was awarded by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $160,125 award to Baylor College of Medicine aims to explore the use of the microbiome to deliver growth factors that promote survival and proliferation of radioresistant intestinal stem cells. The objective is to assess a genetically...
- This Project Grant award of $157,400 from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an effective medical countermeasure against gastrointestinal acute radiation syndrome (GI-ARS). The primary objective is to establish the efficacy of Maroon Biotech's MP8800 copolymer in increasing 10-day and 30-day survival rates, as well as preserving gut barrier function, in a well-established rat model of GI-ARS. The research is...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) totaling $157,000.00 is supporting research to develop a new class of radiation mitigating agents as medical countermeasures for hematopoietic acute radiation syndrome (H-ARS). The principal investigators from the collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences will examine the mitigating effects of the small molecule...
- This $164,500 Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports the development and validation of human normal tissue patient-derived organoids (NT-PDOs) for pre-screening new candidate gastrointestinal (GI) radiation countermeasure drugs. The goal is to create an extracorporeal model based on healthy human GI tissue that can accurately assess the efficacy and safety of radiation mitigators, addressing limitations of...
- This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) is for the development of a thrombopoietin mimetic (TPOM) as a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). The total award amount is $593,823 with a project period from December 2024 to November 2029. The primary awardee, Albert Einstein College of Medicine, is collaborating with The Henry M. Jackson Foundation for the...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $155,857 Project Grant under the Trans-NIH Research Support (CFDA 93.310) program to Signablok, Inc. in Massachusetts. The funding supports the development of a novel medical countermeasure to mitigate potentially lethal acute radiation syndrome (ARS). The project aims to create a well-tolerable and effective first-in-class therapeutic that can be administered at least 24 hours post-radiation exposure...